FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBoston Scientific Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BSX
Boston Scientific Corporation Stock AnalysisComprehensive stock analysis for Boston Scientific Corporation (BSX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBSX
BSX
Boston Scientific Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BSX
  1. Home
  2. Stocks
  3. Boston Scientific Corporation

Boston Scientific Corporation

🇺🇸BSX•NYSE

Boston Scientific Corporation

🇺🇸BSX•NYSE
Market cap
$63.33B
Sentiment

Your view on BSX

Mkt Cap
$63.33B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Boston Scientific Corporation

Industry
Medical - Devices
Sector
Healthcare
CEO
Michael F. Mahoney
Headquarters
300 Boston Scientific Way, Marlborough, MA, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Michael F. Mahoney
Headquarters
300 Boston Scientific Way, Marlborough, MA, US
Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.

The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.

In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies.

Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer.

The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Boston Scientific Corporation from FRC's valuation model, read against the market price. BSX last traded at $43.69, 18.5× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Boston Scientific Corporation. Starting points for Boston Scientific Corporation: P/E 18.5, EPS $2.41, beta 0.58 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Boston Scientific Corporation. Boston Scientific Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Boston Scientific Corporation. Trailing twelve-month EPS for Boston Scientific Corporation stands at $2.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$56.58

average of 24 firms, last 12 months

 

$56.58

Low $44.00

Median $51.50

High $115.00

 

Analyst Ratings

Buy25 firms, last 12 months
  • Strong Buy0
  • Buy18
  • Hold7
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.78$0.75$3.16$3.12
Low estimate$0.77$0.73$3.15$3.05
High estimate$0.79$0.80$3.17$3.21
No. of analysts15101616
Year-ago EPS$0.80$0.80$1.94—
Growth-3.1%-6.7%+63.0%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$5.18B$5.06B$20.97B$20.79B
Low estimate$5.13B$4.86B$20.91B$20.50B
High estimate$5.29B$5.49B$21.11B$21.59B
No. of analysts15102121
Year-ago revenue$5.29B$5.20B$20.07B—
Growth-2.0%-2.7%+4.5%—
Recent analyst actions15 rating and price-target changes, latest Oct 30, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Boston Scientific Corporation. Boston Scientific Corporation has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BSX20 companies · 8 funds
Compare BSX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ANGOAngioDynamics, Inc.Medical - Instruments & Supplies$495M
  • ATRCAtriCure, Inc.Medical - Instruments & Supplies$2.8B
  • CNMDCONMED CorporationMedical - Devices$1.5B
  • CVRXCVRx, Inc.Medical - Devices$17M
  • EWEdwards Lifesciences CorporationMedical - Devices$61.6B
  • LIVNLivaNova PLCMedical - Devices$5.1B
  • MDTMedtronic plcMedical - Devices$131.6B
  • MMSIMerit Medical Systems, Inc.Medical - Instruments & Supplies$5.2B

More Medical - Devices companies

  • NHNKFNihon Kohden CorporationOTC$2.4B
  • NHNKYNihon Kohden CorporationOTC$3.7B
  • NMRDNemaura Medical Inc.OTC$404
  • NMTCNeuroOne Medical Technologies CorporationNASDAQ$7M
  • NNOXNano-X Imaging Ltd.NASDAQ$25M
  • NPCENeuroPace, Inc.NASDAQ$275M
  • NSPRInspireMD, Inc.NASDAQ$28M
  • NSYSNortech Systems IncorporatedNASDAQ$35M
  • NUMDNu-Med Plus, Inc.OTC$1M
  • NUWENuwellis, Inc.NASDAQ$413,060
  • NVCRNovoCure LimitedNASDAQ$1.3B
  • NVNOenVVeno Medical CorporationNASDAQ$4M

ETFs holding Boston Scientific Corporation

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.09%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.08%
  • IVViShares Core SP 500 ETF$852.9B in assets0.10%
  • SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.10%
  • HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.77%
  • IHIiShares US Medical Devices ETF$4.0B in assets3.91%
  • FXHFirst Trust Health Care AlphaDEX Fund$1.2B in assets1.82%
  • BAFEBrown Advisory Flexible Equity ETF$1.7B in assets1.72%

Largest holders first, then the funds most concentrated in BSX.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Boston Scientific Corporation, and how their positions are changing. At a $63.33B market value, institutional positions materially move Boston Scientific Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Boston Scientific Corporation executives and directors. Shares of Boston Scientific Corporation have traded between $85.98 and $109.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Boston Scientific Corporation. Boston Scientific Corporation is a $63.33B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Boston Scientific Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Boston Scientific Corporation. Coverage tracks Boston Scientific Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Boston Scientific Corporation.

BSX Analysis
Fair
Past1
Growth5
Health3
Profit3
Value2

News

Latest Market News